A total of 5,787 preguideline patients and 17,832 postguideline patients were identified. Baseline lipid testing rates were 8.4% for the preguideline cohort and 10.5% for the postguideline cohort, and the 12-week testing rates were 6.8% and 9.0%, respectively. Baseline glucose testing rates were 17.3% for the preguideline cohort and 21.8% for the postguideline cohort, and the 12-week testing rates were 14.1 and 17.9%, respectively.
Metabolic complications of these drugs occur gradually and are heralded by weight gain and laboratory changes. Adherence to the monitoring guidelines would make them much safer drugs.
As I’ve said many times drug safety is more about how doctors use drugs than it is about drugs’ inherent properties.